DB1598Z
Brachytherapy Pleura to None with Iridium 192 (Ir-192), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | B Respiratory System |
| Operation | 1 Brachytherapy |
| Body Part | 5 Pleura |
| Approach | 9 High Dose Rate (HDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the respiratory system places a radioactive source directly inside or immediately next to lung or airway tissue, most often through a bronchoscope that guides a catheter to the tumor site. This lets clinicians deliver a concentrated dose to a small area, such as a tumor growing into the bronchus and narrowing the airway, while sparing surrounding lung tissue that an external beam would have to pass through.
It is frequently used to relieve breathing difficulty caused by an obstructing endobronchial tumor, and it can also serve as a targeted boost after a course of external beam treatment. The radioactive source may be left in place temporarily during a single procedure or, less commonly, implanted for a longer period.
Anatomy & Axis Detail
Pleura
Brachytherapy of the pleura involves placing radioactive sources against or within the pleural space, most often intraoperatively after surgical resection or debulking of malignant pleural mesothelioma, to deliver concentrated dose to residual disease along the chest wall lining. Because the pleura forms a large, curved surface area following the contours of the lung and rib cage, source placement must be planned to achieve even coverage across an irregular geometry while protecting the lung, heart, and diaphragm from excessive dose. This approach is typically used as an adjunct to surgery rather than as a standalone treatment. Coders should confirm that sources are placed against the pleural surface itself, distinguishing this from beam radiation directed at the same region from outside the body.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
Coding this family depends on documentation confirming that a radioactive source was placed within or adjacent to respiratory tissue, including the specific structure treated, the isotope or source type, and whether the implant was temporary or intended to remain in place. The procedure note from the bronchoscopy or interventional session is the key source document. A common mistake is coding the catheter or applicator placement itself as a separate Medical and Surgical procedure when it was performed solely to deliver the radiation, rather than recognizing it as part of the brachytherapy episode. Coders also sometimes miss the qualifier distinguishing a temporary source from a permanent one.
Commonly Confused With
The main point of confusion is with beam radiation, since both treat similar tumors - the distinction is strictly whether the radiation source is inserted into the body or delivered from an external device. It can also be confused with a diagnostic or therapeutic bronchoscopy performed for other reasons; if the bronchoscope is used purely as the delivery route for a radioactive source, the encounter is coded as brachytherapy rather than as a separate endoscopic procedure.